APELLIS Financial Statements From 2010 to 2025
| 1JK Stock | EUR 22.71 0.67 2.87% |
Check APELLIS PHARMACTDL-0001 financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among APELLIS PHARMACTDL-0001's main balance sheet or income statement drivers, such as , as well as many indicators such as . APELLIS financial statements analysis is a perfect complement when working with APELLIS PHARMACTDL-0001 Valuation or Volatility modules.
APELLIS |
APELLIS PHARMACTDL 0001 Company Shares Owned By Insiders Analysis
APELLIS PHARMACTDL-0001's Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current APELLIS PHARMACTDL-0001 Shares Owned By Insiders | 15.32 % |
Most of APELLIS PHARMACTDL-0001's fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, APELLIS PHARMACTDL 0001 is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 15.321% of APELLIS PHARMACTDL 0001 are shares owned by insiders. This indicator is about the same for the Healthcare average (which is currently at 15.18) sector and 8.05% higher than that of the Biotechnology industry. The shares owned by insiders for all Germany stocks is 51.84% lower than that of the firm.
APELLIS PHARMACTDL 0001 Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining APELLIS PHARMACTDL-0001's current stock value. Our valuation model uses many indicators to compare APELLIS PHARMACTDL-0001 value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across APELLIS PHARMACTDL-0001 competition to find correlations between indicators driving APELLIS PHARMACTDL-0001's intrinsic value. More Info.APELLIS PHARMACTDL 0001 is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the APELLIS PHARMACTDL-0001's earnings, one of the primary drivers of an investment's value.About APELLIS PHARMACTDL-0001 Financial Statements
APELLIS PHARMACTDL-0001 stakeholders use historical fundamental indicators, such as APELLIS PHARMACTDL-0001's revenue or net income, to determine how well the company is positioned to perform in the future. Although APELLIS PHARMACTDL-0001 investors may analyze each financial statement separately, they are all interrelated. For example, changes in APELLIS PHARMACTDL-0001's assets and liabilities are reflected in the revenues and expenses on APELLIS PHARMACTDL-0001's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in APELLIS PHARMACTDL 0001. Please read more on our technical analysis and fundamental analysis pages.
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts. APELLIS PHARMACT operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 445 people.
Currently Active Assets on Macroaxis
Other Information on Investing in APELLIS Stock
APELLIS PHARMACTDL-0001 financial ratios help investors to determine whether APELLIS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in APELLIS with respect to the benefits of owning APELLIS PHARMACTDL-0001 security.